The European Medicines Agency (EMA) and Heads of Medicines Agencies (HMA) have published their joint strategy for the next five years.
The strategy sets out how the European medicines regulatory network can continue to enable patient access to safe and effective medicines in response to the challenges presented by developments in science and medicine, globalisation and health threats, such as COVID-19.
The strategy is aligned with the European Commission’s Pharmaceutical Strategy and outlines six priority areas for which strategy goals will be translated into concrete actions. These areas are: the availability and accessibility of medicines; data analytics, digital tools and digital transformation; innovation; antimicrobial resistance and other emerging health threats; supply chain challenges and the sustainability of the network and operational excellence. Recent developments relating to the COVID-19 pandemic have also been incorporated into the strategy.
Emer Cooke, Executive Director of EMA, said: “The COVID-19 pandemic has highlighted the pivotal role of medicine regulation for the protection of public health. Lack of availability of medicines, either because they are not marketed or due to supply disruptions, has shown to pose serious threats to patient and animal health, animal disease control programs and sustainable livestock production. This strategy ensures that we join forces across the EU to effect tangible improvements for citizens.”
Read the EMA article for further information.